Biophytis Unveils Ambitious 2025 Roadmap: Expanding Therapeutic Pipeline and Global Presence

Biophytis SA, a clinical-stage biotechnology company specializing in age-related diseases, has outlined its strategic roadmap for 2025, focusing on expanding its therapeutic pipeline and global presence. The company, headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil, is poised to accelerate the clinical development and commercialization of its lead drug candidate, BIO101 (20-Hydroxyecdysone), through a series of strategic initiatives.



Biophytis' 2025 roadmap includes several key developments aimed at expanding its therapeutic pipeline and addressing major medical needs. The company plans to launch the OBA clinical development program for the treatment of obesity, targeting a rapidly expanding market estimated to reach $100 billion by 2030. This initiative, in collaboration with Blanver and other potential partners, will evaluate the efficacy of BIO101 (20-Hydroxyecdysone) in obese patients treated with GLP-1 RAs and following a hypocaloric diet. Additionally, Biophytis has signed a co-development agreement with AskHelpU in ALS, exploring the potential of BIO101 in a new indication and further diversifying its therapeutic pipeline.



Biophytis' strategic roadmap also emphasizes strengthening its global presence and impact across key geographies. The company has entered exclusive negotiations with a major Chinese pharmaceutical company to license BIO101, expanding its reach in the Asian market. Furthermore, Biophytis has concluded a co-development agreement with AskHelpU in ALS, enabling the company to address crucial public health issues in multiple regions and consolidate its growth and impact.



Biophytis plans to launch phase 3 of its SARA clinical program in the coming months, aimed at confirming the efficacy of BIO101 (20-Hydroxyecdysone) in sarcopenia. This indication represents a major unresolved public health issue, with a rapidly expanding market representing some 30 million patients in China and a growing prevalence in Europe and the United States. By accelerating the clinical development and commercialization of BIO101, Biophytis aims to bring therapeutic solutions to patients in need while consolidating its growth and impact across all key geographies.



In conclusion, Biophytis' strategic roadmap for 2025 aligns with its long-term vision for growth and impact in key geographies. By expanding its therapeutic pipeline, strengthening its global presence, and accelerating the clinical development and commercialization of BIO101, Biophytis is well-positioned to address major medical needs and consolidate its growth and impact across all key geographies. As the company continues to execute its roadmap, investors should monitor its progress and consider the potential opportunities and risks associated with its ambitious plans.